[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603140":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":55,"centralContacts":59,"locations":60,"responsibleParty":81,"collaborators":83,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":59,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":59,"enrollmentInfo":96,"targetDuration":59,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":59,"overallStatus":63,"whyStopped":59,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"University of Michigan Rogel Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Basic science ([68Ga] Ga-FAPI-04)","EXPERIMENTAL","Patients receive \\[68Ga\\] Ga-FAPI-04 IV, followed 1 hour later by PET\u002FCT scan over approximately 25 minutes.",[13,14,15],"Procedure: Computed Tomography","Drug: Gallium Ga 68-DOTA-FAPI-04","Procedure: Positron Emission Tomography",[17,33,43],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"PROCEDURE","Computed Tomography","Undergo CT scan",[9],[23,24,25,26,27,28,29,30,31,32],"CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","tomography",{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"DRUG","Gallium Ga 68-DOTA-FAPI-04","Given IV",[9],[39,40,41,42],"68Ga-DOTA-FAPI-04","68Ga-FAPi-04","GALLIUM GA-68-DOTA-FAPI-04","Gallium-68-FAPi-04",{"type":18,"name":44,"description":45,"armGroupLabels":46,"otherNames":47},"Positron Emission Tomography","Undergo PET scan",[9],[48,49,50,51,52,53,54],"Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron emission tomography (procedure)","Positron Emission Tomography Scan","Positron-Emission Tomography","PT",[56],{"name":57,"affiliation":5,"role":58},"Benjamin Viglianti","PRINCIPAL_INVESTIGATOR",null,[61],{"facility":62,"status":63,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"University of Michigan Comprehensive Cancer Center","RECRUITING","Ann Arbor","Michigan","48109","United States","US",{"type":70,"coordinates":71},"Point",[72,73],-83.74088,42.27756,{"lat":73,"lon":72},[76,80],{"name":57,"role":77,"phone":78,"phoneExt":59,"email":79},"CONTACT","734-936-5385","bviglia@med.umich.edu",{"name":57,"role":58,"phone":59,"phoneExt":59,"email":59},{"type":82,"investigatorFullName":59,"investigatorTitle":59,"investigatorAffiliation":59,"oldNameTitle":59,"oldOrganization":59},"SPONSOR",[84],{"name":85,"class":86},"Neuroendocrine Research Foundation","UNKNOWN","100603140","early-phase-1-an-investigational-scan-68ga-ga-fapi-04-petct-for-the-imaging-of-patients-with-high-grade-neuroendocrine-cancer-100603140",false,"NCT07132645","An Investigational Scan ([68Ga] Ga-FAPI-04 PET\u002FCT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer","An Exploratory Study of [68Ga]Ga-Fibroblast Activation Protein Inhibitor 4 ([68Ga]Ga-FAPI-04) in Patients With High-Grade Neuroendocrine Neoplasms","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Current neuroendocrine tumor diagnosis AND high-grade neuroendocrine tumor presentation determined using the following criteria(s):\n\n  * Previous low uptake of \\[68Ga\\] Ga-DOTATATE PET\u002FCT scan OR\n  * Krenning Score ≥ 3 OR\n  * Ki67 index ≥ 20%\n* Able to lie flat for 60 minutes\n* Ability to understand and the willingness to sign a written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Patient recently underwent surgery with wound healing","ALL","18 Years",{"count":97,"type":98},30,"ESTIMATED","INTERVENTIONAL",[101],"EARLY_PHASE1","This early phase I trial determines where and to what degree the tracer \\[68Ga\\] Ga-FAPI-04 accumulates in normal and cancer tissues in patients with high grade neuroendocrine cancer. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research \\[68Ga\\] Ga-FAPI-04. Because some cancers take up \\[68Ga\\] Ga-FAPI-04, it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body.",[104],"Neuroendocrine Tumor","2025-09-22",{"date":107,"type":108},"2025-09-23","ACTUAL",{"date":110,"type":108},"2025-09-16",{"date":112,"type":98},"2027-09-01",{"name":5,"class":6},1]